UnitedHealth Group (UNH)
(Delayed Data from NYSE)
$565.29 USD
+6.53 (1.17%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $565.44 +0.15 (0.03%) 6:38 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
UnitedHealth Group (UNH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$619.61 | $680.00 | $560.00 | 10.89% |
Price Target
Based on short-term price targets offered by 23 analysts, the average price target for UnitedHealth Group comes to $619.61. The forecasts range from a low of $560.00 to a high of $680.00. The average price target represents an increase of 10.89% from the last closing price of $558.76.
Analyst Price Targets (23)
Broker Rating
UnitedHealth Group currently has an average brokerage recommendation (ABR) of 1.06 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms. The current ABR compares to an ABR of 1.15 a month ago based on 24 recommendations.
Of the 25 recommendations deriving the current ABR, 23 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 92% and 8% of all recommendations. A month ago, Strong Buy made up 87.5%, while Buy represented 8.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/UNH.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 23 | 23 | 21 | 21 | 18 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 1 | 1 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.06 | 1.06 | 1.15 | 1.15 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/18/2024 | UBS | Kevin Caliendo | Strong Buy | Strong Buy |
7/17/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/17/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/17/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/17/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
7/17/2024 | Argus Research Corp. | David A Toung | Not Available | Strong Buy |
7/17/2024 | Truist Securities | David S Macdonald | Strong Buy | Strong Buy |
7/17/2024 | Not Identified | Not Identified | Hold | Strong Buy |
7/17/2024 | Wells Fargo Securities | Stephen Baxter | Strong Buy | Strong Buy |
7/16/2024 | SVB Securities | Whit Mayo | Strong Buy | Strong Buy |
7/11/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/9/2024 | Cantor Fitzgerald & Co | Sarah James | Strong Buy | Strong Buy |
6/18/2024 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
6/5/2024 | Not Identified | Not Identified | Hold | Strong Buy |
5/30/2024 | Robert W. Baird & Co. | Michael Ha | Not Available | Strong Buy |
5/28/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
5/1/2024 | Stephens | Scott Fidel | Strong Buy | Strong Buy |
4/17/2024 | Piper Sandler | Jessica E Tassan | Strong Buy | Strong Buy |
4/16/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
12/25/2023 | Goldman Sachs | Nathan Rich | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.06 |
ABR (Last week) | 1.06 |
# of Recs in ABR | 25 |
Average Target Price | $619.61 |
LT Growth Rate | 13.00% |
Industry | Medical - HMOs |
Industry Rank by ABR | 195 of 253 |
Current Quarter EPS Est: | 7.05 |